Benflumetol - CAS 82186-77-4
Catalog number: 82186-77-4
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Benflumetol, also known as HSDB 7210, is an antimalarial drug used to treat acute uncomplicated malaria. It is used in combination with Artemether for improved efficacy. It inhibits hemozoin formation. It is is an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.
Publictions citing BOC Sciences Products
  • >> More
Yellow Solid
Lumefantrine;(9Z)-2,7-Dichloro-9-[(4-chlorophenyl)methylene]-a-[(dibutylamino)methyl]-9H-fluorene-4-methanol;2-Dibutylamino-1-[2,7-dichloro-9-[1-(4-chlorophenyl)meth-(Z)-ylidene]-9H-fluoren-4-yl]ethanol;(Z)-2-(Dibutylamino)-1-(2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl)ethanol 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]fluoren-4-yl]ethanol
10 mM in DMSO
-20°C Freezer
Benflumetol is used in combination with Artemether for improved efficacy. It inhibits hemozoin formation. It is is an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.
Quality Standard:
In-house standard
Shelf Life:
2 month in rt, long time
Kilogram to ton
Boiling Point:
642.5±55.0 °C | Condition: Press: 760 Torr
Melting Point:
1.252±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
Canonical SMILES:
Current Developer:
Benflumetol has been listed.
1.Primaquine plus artemisinin combination therapy for reduction of malaria transmission: promise and risk.
John CC1. BMC Med. 2016 Apr 1;14(1):65. doi: 10.1186/s12916-016-0611-9.
Reduction of gametocyte transmission from humans to mosquitoes is a key component of malaria elimination. The study by Gonçalves and colleagues provides valuable new data on how the addition of low-dose primaquine to artemether-lumefantrine affects reduction of gametocytemia and transmission of gametocytes to mosquitoes in asymptomatically Plasmodium falciparum-infected children without G6PD deficiency, and on the degree to which low-dose primaquine affects hemoglobin levels in these children. The study sets the stage for future research required for consideration of an artemisinin combination therapy (ACT)-primaquine regimen in mass drug administration campaigns. Future studies will need to evaluate toxicity in adults and G6PD deficient persons, assess gametocyte transmission from adults, evaluate different ACT drugs with primaquine, and assess the implications of "rare" toxicities in large treatment populations, such as hemolysis requiring blood transfusion.
2.CRISPR-Cas9-modified pfmdr1 protects Plasmodium falciparum asexual blood stages and gametocytes against a class of piperazine-containing compounds but potentiates artemisinin-based combination therapy partner drugs.
Ng CL1, Siciliano G2, Lee MC1, de Almeida MJ, Corey VC3, Bopp SE3, Bertuccini L4, Wittlin S5, Kasdin RG1, Le Bihan A6, Clozel M6, Winzeler EA3, Alano P2, Fidock DA1,7. Mol Microbiol. 2016 Apr 12. doi: 10.1111/mmi.13397. [Epub ahead of print]
Emerging resistance to first-line antimalarial combination therapies threatens malaria treatment and the global elimination campaign. Improved therapeutic strategies are required to protect existing drugs and enhance treatment efficacy. We report that the piperazine-containing compound ACT-451840 exhibits single-digit nanomolar inhibition of the Plasmodium falciparum asexual blood stages and transmissible gametocyte forms. Genome sequence analyses of in vitro-derived ACT-451840-resistant parasites revealed single nucleotide polymorphisms in pfmdr1, which encodes a digestive vacuole membrane-bound ABC transporter known to alter P. falciparum susceptibility to multiple first-line antimalarials. CRISPR-Cas9 based gene editing confirmed that PfMDR1 point mutations mediated ACT-451840 resistance. Resistant parasites demonstrated increased susceptibility to the clinical drugs lumefantrine, mefloquine, quinine, and amodiaquine. Stage V gametocytes harboring Cas9-introduced pfmdr1 mutations also acquired ACT-451840 resistance.
3.Quality Assessment of Artemether-Lumefantrine Samples and Artemether Injections Sold in the Cape Coast Metropolis.
Prah J1, Ameyaw EO2, Afoakwah R2, Fiawoyife P3, Oppong-Danquah E3, Boampong JN2. J Trop Med. 2016;2016:8602619. doi: 10.1155/2016/8602619. Epub 2016 Feb 23.
Most prescribers and patients in Ghana now opt for the relatively expensive artemether/lumefantrine rather than artesunate-amodiaquine due to undesirable side effects in the treatment of uncomplicated malaria. The study sought to determine the existence of substandard and/or counterfeit artemether-lumefantrine tablets and suspension as well as artemether injection on the market in Cape Coast. Six brands of artemether-lumefantrine tablets, two brands of artemether-lumefantrine suspensions, and two brands of artemether injections were purchased from pharmacies in Cape Coast for the study. The mechanical properties of the tablets were evaluated. The samples were then analyzed for the content of active ingredients using High Performance Liquid Chromatography with a variable wavelength detector. None of the samples was found to be counterfeit. However, the artemether content of the samples was variable (93.22%-104.70% of stated content by manufacturer).
4.Risk factors for Plasmodium falciparum and Plasmodium vivax gametocyte carriage in Papua New Guinean children with uncomplicated malaria.
Karl S1, Laman M2, Moore BR3, Benjamin JM2, Salib M2, Lorry L2, Maripal S2, Siba P2, Robinson LJ4, Mueller I1, Davis TM5. Acta Trop. 2016 Apr 4;160:1-8. doi: 10.1016/j.actatropica.2016.04.002. [Epub ahead of print]
There are limited data on gametocytaemia risk factors before/after treatment with artemisinin combination therapy in children from areas with transmission of multiple Plasmodium species. We utilised data from a randomised trial comparing artemether-lumefantrine (AL) and artemisinin-naphthoquine (AN) in 230 Papua New Guinean children aged 0.5-5 years with uncomplicated malaria in whom determinants of gametocytaemia by light microscopy were assessed at baseline using logistic regression and during follow-up using multilevel mixed effects modelling. Seventy-four (32%) and 18 (8%) children presented with P. falciparum and P. vivax gametocytaemia, respectively. Baseline P. falciparum gametocytaemia was associated with Hackett spleen grade 1 (odds ratio (95% CI) 4.01 (1.60-10.05) vs grade 0; P<0.001) and haemoglobin (0.95 (0.92-0.97) per 1g/L increase; P<0.001), and P. falciparum asexual parasitaemia in slide-positive cases (0.36 (0.19-0.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products

CAS 935467-97-3 TH-237A

(CAS: 935467-97-3)

TH-237A(meso-GS 164) is a novel neuroprotective agent exhibiting favorable permeation across the blood brain barrier.

CAS 369377-66-2 BigLEN (rat)

BigLEN (rat)
(CAS: 369377-66-2)

BigLEN (rat) is a proSAAS-derived peptide that acts as a potent GPR171 agonist (EC50 = 1.6 nM). It regulates body weight in mice and promotes the outgrowth of n...

CAS 222638-67-7 BEC HCl

(CAS: 222638-67-7)

BEC HCl is an Arginase II inhibitor(Ki=0.31μM).In vitro,BEC HCl enhances NO-dependent smooth muscle relaxation by binding to arginase as a transition state anal...

CAS 55290-63-6 Atractylodin

(CAS: 55290-63-6)

Atractylodin is an active component of the essential oil contained in the rhizomes of Atractylodes lancea and A.

CAS 1141777-14-1 Emixustat

(CAS: 1141777-14-1)

Emixustat, a novel visual cycle modulator, is a nonretinoid compound that directly inhibits RPE65, but does not bind to RAR/<br/>RXR retinoid receptors or antag...

(CAS: 124307-91-1)

PYR-791 is an important synthetic intermediate for a lot of bio-active molecules, including porphyrins, bile pigments, photosensitizers, anticancer agents.

CAS 1641-17-4 Mexenone

(CAS: 1641-17-4)

Mexenone, the derivative of benzophenone, is a sunscreening agent.

CAS 130273-87-9 15(R)-17-phenyl trinor Prostaglandin F2α isopropyl ester

15(R)-17-phenyl trinor Prostaglandin F2α
(CAS: 130273-87-9)

15(R)-17-phenyl trinor Prostaglandin F2α isopropyl ester is a potential impurity in most commercial preparations of the latanoprost bulk drug product. The IC50 ...

CAS 524708-03-0 APE1 Inhibitor III

APE1 Inhibitor III
(CAS: 524708-03-0)

APE1 Inhibitor III is a selective and competitive inhibitor of apurinic/apyrimidinic (AP) endonuclease 1 (APE1) with 2.0 micromolar activity against the purifie...

CAS 1161233-85-7 BTZ043

(CAS: 1161233-85-7)

The new antitubercular drug candidate 2-[2-S-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (BTZ043) targets th...

CAS 6055-19-2 Cyclophosphamide Monohydrate

Cyclophosphamide Monohydrate
(CAS: 6055-19-2)

Cyclophosphamide Monohydrate is a nitrogen mustard alkylating agent, it attaches the alkyl group to the guanine base of DNA. It is used to treat cancers and aut...

CAS 465-90-7 Hellebrigenin

(CAS: 465-90-7)

Hellebrigenin is an anticancer agent that induces DNA damage, mitochondria collapse, cell cycle arrest and apoptosis.

CAS 1164500-72-4 ML 145

ML 145
(CAS: 1164500-72-4)

ML 145 is a GPR35 orphan receptor antagonist with IC50 value of 20.1 nM. It can be used in the treatment of disorders affecting the stomach as well as the immun...

CAS 510721-85-4 AR03

(CAS: 510721-85-4)

AR03 is a specific inhibitor of apurinic/apyrimidinic (AP) endonuclease 1 (APE1).

(CAS: 307316-55-8)

BMS-247243 is a novel β-Lactamase inhibitor which is a family of enzymes involved in bacterial resistance to beta-lactam antibiotics.

P21d hydrochloride

P21d hydrochloride is a breast tumor kinase inhibitor with IC50 value of 30 nM. It can restore E-cadherin expression and suppress migration in breast cancer cel...

CAS 63238-66-4 Benzoylhypacoitine

(CAS: 63238-66-4)

Benzoylhypacoitine is extracted from the roots of Aconitum carmichaeli Debx. It might be the principal active components which affect mitochondrial growth by Fu...

(CAS: 112227-15-3)

CP-71362 is a pentapeptide renin inhibitor. It is selective for the canine enzyme.

CAS 103766-25-2 Gimeracil

(CAS: 103766-25-2)

Gimeracil is a pyridine derivative with antitumor activity. Gimeracil enhances the antitumor activity of fluoropyrimidines by competitively and reversibly inhib...

(CAS: 1269181-69-2)

Nicodicosapent is a bio-active molecular as an antihypertrigylceridemic drug candidate.

Chemical Structure

CAS 82186-77-4 Benflumetol

Quick Inquiry

Verification code

Featured Items